Valuation: Titan Pharmaceuticals, Inc.

Market Cap 6.13M 5.48M 5.11M 4.63M 8.72M 584M 8.78M 61.06M 23.91M 303M 23.03M 22.52M 971M P/E 2023
-1.11x
P/E 2024 -0.62x
Enterprise Value 3.3M 2.95M 2.75M 2.49M 4.69M 315M 4.73M 32.87M 12.87M 163M 12.4M 12.13M 523M EV / Sales 2023
0.11x
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -

Financials

2023 2024
Net sales 184K 164K 153K 139K 262K 17.53M 264K 1.83M 717K 9.08M 691K 676K 29.14M -
Net income -5.57M -4.97M -4.64M -4.2M -7.92M -531M -7.98M -55.45M -21.71M -275M -20.91M -20.45M -882M -4.71M -4.2M -3.92M -3.55M -6.69M -448M -6.74M -46.86M -18.35M -232M -17.67M -17.28M -745M
Net Debt -6.2M -5.53M -5.16M -4.67M -8.81M -590M -8.87M -61.68M -24.15M -306M -23.27M -22.75M -981M -2.83M -2.53M -2.36M -2.14M -4.03M -270M -4.05M -28.19M -11.04M -140M -10.63M -10.4M -448M
Logo Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
Employees
-
Sector
-